文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

解决中低收入国家的艾滋病治愈问题。

Addressing an HIV cure in LMIC.

机构信息

Division of Medical Virology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, 7925, South Africa.

Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, N6A5C1, Canada.

出版信息

Retrovirology. 2021 Aug 3;18(1):21. doi: 10.1186/s12977-021-00565-1.


DOI:10.1186/s12977-021-00565-1
PMID:34344423
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8330180/
Abstract

HIV-1 persists in infected individuals despite years of antiretroviral therapy (ART), due to the formation of a stable and long-lived latent viral reservoir. Early ART can reduce the latent reservoir and is associated with post-treatment control in people living with HIV (PLWH). However, even in post-treatment controllers, ART cessation after a period of time inevitably results in rebound of plasma viraemia, thus lifelong treatment for viral suppression is indicated. Due to the difficulties of sustained life-long treatment in the millions of PLWH worldwide, a cure is undeniably necessary. This requires an in-depth understanding of reservoir formation and dynamics. Differences exist in treatment guidelines and accessibility to treatment as well as social stigma between low- and-middle income countries (LMICs) and high-income countries. In addition, demographic differences exist in PLWH from different geographical regions such as infecting viral subtype and host genetics, which can contribute to differences in the viral reservoir between different populations. Here, we review topics relevant to HIV-1 cure research in LMICs, with a focus on sub-Saharan Africa, the region of the world bearing the greatest burden of HIV-1. We present a summary of ART in LMICs, highlighting challenges that may be experienced in implementing a HIV-1 cure therapeutic. Furthermore, we discuss current research on the HIV-1 latent reservoir in different populations, highlighting research in LMIC and gaps in the research that may facilitate a global cure. Finally, we discuss current experimental cure strategies in the context of their potential application in LMICs.

摘要

尽管经过多年的抗逆转录病毒疗法 (ART),HIV-1 仍在受感染个体中持续存在,这是由于形成了稳定且寿命长的潜伏病毒库。早期的 ART 可以减少潜伏库,并与 HIV 感染者(PLWH)的治疗后控制相关。然而,即使在治疗后控制者中,一段时间后停止 ART 不可避免地会导致血浆病毒血症反弹,因此需要终身抑制病毒治疗。由于全球数百万 HIV 感染者持续终生治疗的困难,治愈无疑是必要的。这需要深入了解储库的形成和动态。中低收入国家(LMICs)和高收入国家在治疗指南、治疗可及性以及社会污名化方面存在差异。此外,来自不同地理区域的 PLWH 存在人口统计学差异,例如感染的病毒亚型和宿主遗传学,这可能导致不同人群之间的病毒库存在差异。在这里,我们综述了 LMIC 中与 HIV-1 治愈研究相关的主题,重点关注承载 HIV-1 最大负担的撒哈拉以南非洲地区。我们总结了 LMIC 中的 ART,强调了在实施 HIV-1 治愈疗法时可能遇到的挑战。此外,我们讨论了不同人群中 HIV-1 潜伏库的当前研究,重点介绍了 LMIC 的研究以及可能促进全球治愈的研究空白。最后,我们在其在 LMIC 中的潜在应用背景下讨论了当前的实验治愈策略。

相似文献

[1]
Addressing an HIV cure in LMIC.

Retrovirology. 2021-8-3

[2]
Reduce and Control: A Combinatorial Strategy for Achieving Sustained HIV Remissions in the Absence of Antiretroviral Therapy.

Viruses. 2020-2-8

[3]
A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure.

Curr HIV Res. 2021

[4]
Deep latency: A new insight into a functional HIV cure.

EBioMedicine. 2019-6-18

[5]
Myeloid and CD4 T Cells Comprise the Latent Reservoir in Antiretroviral Therapy-Suppressed SIVmac251-Infected Macaques.

mBio. 2019-8-20

[6]
From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.

Bioessays. 2013-4-24

[7]
In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure.

Annu Rev Pathol. 2022-1-24

[8]
Interventions during Early Infection: Opening a Window for an HIV Cure?

Viruses. 2024-10-9

[9]
Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.

Viruses. 2020-4-27

[10]
Selective BCL-X Antagonists Eliminate Infected Cells from a Primary-Cell Model of HIV Latency but Not from Reservoirs.

J Virol. 2021-7-12

引用本文的文献

[1]
Role of Artificial Intelligence and Personalized Medicine in Enhancing HIV Management and Treatment Outcomes.

Life (Basel). 2025-5-6

[2]
Challenges of integrating HIV prevention and treatment in China's border mountain regions: a grounded theory study.

BMC Infect Dis. 2025-5-9

[3]
Model-based evaluation of the impact of a potential HIV cure on HIV transmission dynamics.

Nat Commun. 2025-4-22

[4]
Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries.

Viruses. 2025-1-6

[5]
Advancing HIV cure research in low- and middle-income countries requires empowerment of the next generation of scientists.

J Virus Erad. 2024-3-6

[6]
Effective and targeted latency reversal in CD4 T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection.

Emerg Microbes Infect. 2024-12

[7]
High-resolution Inference of Multiplexed Anti-HIV Gene Editing using Single-Cell Targeted DNA Sequencing.

bioRxiv. 2024-8-22

[8]
Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome-An Extempore Game of Misfiring with Defense Arsenals.

Pathogens. 2023-1-29

[9]
Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda.

Retrovirology. 2022-1-15

本文引用的文献

[1]
Specialized DNA Structures Act as Genomic Beacons for Integration by Evolutionarily Diverse Retroviruses.

Viruses. 2023-2-7

[2]
Intra-Clade C signature polymorphisms in HIV-1 LTR region: The Indian and African lookout.

Virus Res. 2021-5

[3]
Characteristics of HIV seroconverters in the setting of universal test and treat: Results from the SEARCH trial in rural Uganda and Kenya.

PLoS One. 2021-2-5

[4]
HIV-1C and HIV-1B Tat protein polymorphism in Southern Brazil.

J Neurovirol. 2021-2

[5]
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

JAMA. 2020-10-27

[6]
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.

Clin Infect Dis. 2021-6-1

[7]
Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.

Lancet HIV. 2020-8-6

[8]
A Stronger Transcription Regulatory Circuit of HIV-1C Drives the Rapid Establishment of Latency with Implications for the Direct Involvement of Tat.

J Virol. 2020-9-15

[9]
A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection.

EBioMedicine. 2020-9

[10]
Reduced HIV-1 latent reservoir outgrowth and distinct immune correlates among women in Rakai, Uganda.

JCI Insight. 2020-7-23

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索